INTRODUCTION

Atopic dermatitis (AD) is one of the most common cutaneous inflammatory and pruritic diseases in dogs. AD is a genetically predisposed inflammatory and pruritic skin disease associated with well-defined clinical signs and immunoglobulin (Ig)E directed against environmental allergens.\(^1\) Atopic-like dermatitis (ADL) is a disease characterized by the same clinical signs of AD in absence of demonstrable IgE.\(^1\) The major difference between these 2 entities resides in the impossibility to demonstrate IgE in ADL, making it impossible to formulate an allergen-specific immunotherapy (ASIT).\(^1\) The true incidence of ADL is unknown, and the therapeutic response to the common therapies for AD is also unknown. In one unpublished study performed in France by Prelaud and Cochet-Fairevere,\(^2\) 25.6% of dogs enrolled were diagnosed with ADL. A similar percentage (14.6%) was present in a more recent study in the United States.\(^3\) A breed predisposition for English bulldogs was also suspected in one of these studies.\(^2\) In addition, the efficacy of cyclosporine (CsA) for such patients is controversial. In the first study, a lower efficacy rate was seen in ADL compared with AD dogs (50% vs 92%)\(^2;\) although in other studies, CsA has been shown to be effective in ADL dogs.\(^3,4\) The effect of more recent drugs on ADL is unknown. The difficulty to treat AD/
ADL dogs resides also in the well-known diversity in clinical presentation and response to treatments within the 2 AD entities. Because of this enormous diversity, canine AD has been recently suggested to be classified as a syndrome more than a well-defined single cutaneous inflammatory entity, as proposed in human AD.5

CANINE ATOPIC DERMATITIS: CLINICAL AND PATHOGENETIC SYNOPSIS

AD is extremely common in dogs, affecting between 3% and 15% of the canine population or up to 58% of dogs affected by skin diseases.6–8 The age of onset typically spans between 6 months and 6 years; however, more than 70% of AD dogs develop clinical signs between 1 and 3 years of age. Many breeds have been associated with AD, with terriers, retrievers, and brachycephalic dogs most commonly affected.9–11

Clinically, canine AD is characterized by chronic skin inflammation, pruritus, and recurrent skin infections. The most common clinical signs include generalized pruritus (seasonal, nonseasonal, or nonseasonal with seasonal worsening), erythema, papules, pustules, crusts, and excoriations.12 Head (perioral, periocular, and ears), flexor aspect of elbows, carpal and tarsal joints, paws (digits, claws, and interdigital aspects), ventral abdomen, perineum, and ventral tail are most commonly affected.12 However, few exceptions have been reported in West Highland white terriers, shar- peis, and German shepherds.13 The diagnosis of canine AD is based on characteristic clinical signs and by excluding other pruritic diseases (eg, food allergy, demodicosis, scabies).12

The pathogenesis of AD is very complex and not completely elucidated. Both genetic and environmental factors are involved in the development of the clinical disease, with both types I and IV hypersensitivity reactions demonstrated. Classically, the first step involved in the development of AD is a sensitization to environmental allergens (eg, house dust mites) penetrating through the skin (mainly) able to lead to recruitment and activation of resident inflammatory cells and degranulation of mast cells via binding to IgE. On activation, multiple inflammatory mediators, including cytokines (specifically type 2 and proinflammatory) and chemokines are secreted, determining the course of the disease. With the chronicity of the lesions, a type 1 inflammatory response predominates. Last, a defect in the epidermal barrier is associated to a higher penetration of allergens through the skin and exacerbation of the inflammatory response. However, if such defect is primary or secondary is still controversial. Other major exacerbating factors include bacterial (*Staphylococcus pseudintermedius*) and fungal (*Malassezia pachydermatis*) infections along with psychogenic and environmental (eg, humidity) factors. Very recently, a series of review articles has been published. The series represents an extensive review on the current knowledge on the pathogenesis of canine AD.14–20 Thus, for more in-depth information, the author refers the reader to such review articles.

Due to the diversity of the phenomena involved in the pathogenesis of canine AD and the variety of clinical presentations, a more rational and tailored therapeutic approach is required for each patient.21,22 Such therapeutic options should be customized for each atopic dog, keeping in consideration the needs of each dog (eg, amount of drugs, side effects, severity of the clinical signs, easy administration of treatments) and the dog’s owners (eg, financial circumstances, expectations, quality of life, time).

TREATMENT OVERVIEW

The treatment of canine AD is mainly centered on 4 factors: time (chronic vs acute lesions), presence of pruritus, inflammation, and infections. The chronicity of the lesions
and their severity will determine the choice of short-term (eg, flare) versus long-term medications, keeping in mind side effects, efficacy, and costs. Finally, cutaneous infections, bacterial and/or fungal, are major exacerbators, and as such need to be properly treated. Topical and systemic options are commercially available to treat AD. For the purpose of this review, only therapies that are available for dogs are discussed in depth. Finally, a discussion on ASIT, injectable or sublingual, is beyond the scope of this review.

TOPICAL THERAPIES

Recently, 2 documents highlighting the guidelines for the treatment of canine AD have shown that the improvement of the skin, and coat hygiene and care is fundamental in treating atopic dogs.\(^21,22\) The skin care can be achieved in several ways by using different products with the goal of moisturizing the skin, reducing the inflammatory and/or pruritic response, and repairing the skin barrier.

MOISTURIZERS

Moisturizers (emollients and/or humectants) have multiple functions. The most important action is increasing the amount of water in the skin by reducing the transepidermal water loss (TEWL) via blocking agents (ie, oils) or using hygroscopic molecules. These latter act as occlusive agents and attract water from the environment and/or from the dermis/subcutaneous tissues (eg, oatmeal). The increase of hydration alone is able to significantly reduce the pruritus and the need of antipruritic drugs; weekly Allermyl shampoo (containing lipids, complex sugars, and antiseptics) for 3 to 4 weeks significantly decreases pruritus and lesional score in most dogs.\(^23,24\)

ANTI-INFLAMMATORY/ANTIPRURITIC

The most important topical anti-inflammatory drugs include glucocorticoids (GCs) and calcineurin inhibitors (CIs); however, antihistamines and local anesthetics have been used in dogs with some success.

GCs are extremely potent and versatile compounds that can be used either systemically or topically. They are generally associated to a significant reduction in both inflammation and pruritus. Their mechanism of action is very broad, complex, and not completely understood. In allergic diseases, they seem to interfere with proinflammatory and pruritogenic mediators, inflammatory cell migration and function, and with inflammation-associated nerve hypersensitivity.\(^25\)

Topical GCs have been largely used during the past decades for the reduced presence of systemic side effects (eg, polyuria, polydipsia, polyphagia, urinary tract infections, and muscle wasting) compared with oral GCs; however, cutaneous atrophy, comedones, and calcinosis cutis are potential side effects for some topical GCs. Based on their chemical structure, topical GCs can be divided into “old” and “new” generation. To the former belong compounds like hydrocortisone, prednisolone, triamcinolone acetonide, betamethasone, and dexamethasone. The new generation includes diester topical GCs, like mometasone furoate, hydrocortisone aceponate, and prednicarbate. These latter are metabolized in situ into inactive molecules, dramatically reducing the presence of systemic side effects.

Triamcinolone acetonide (0.015%, Genesis; Virbac, Fort Worth, TX) spray is the only “old” GC that has been shown to be highly efficacious in the treatment of canine AD. In a multicenter, randomized, double-blinded, placebo/vehicle-controlled clinical trial (RDBPCT),\(^26\) triamcinolone acetonide spray was applied to allergic dogs for 4 weeks
at tapered frequency. At the end of the study, a significant improvement in pruritus,
clinical signs, and overall assessment was present when compared with vehicle in
absence of clinical and minor hematological adverse effects (slightly lower total leuko-
cyte, lymphocyte, and eosinophil counts after treatment).

Similar response has been documented for hydrocortisone aceponate (0.0584%,
Cortavance; Virbac), a “new” GC, through few RDBPCTs trials in Europe and Ko-
tea. In the first clinical trial, Cortavance was administered to dogs with mild
AD for 70 days at tapered frequency. After 28 days of treatment, 73.0% and 46.6% of
dogs achieved a reduction of >50% in clinical score and pruritus, respectively. 
These results were confirmed by a second study comparing the efficacy of daily Cor-
tavance with cyclosporine over 84 days. This study showed the clinical equivalence
between Cortavance and CsA in absence of clinical, hematological, or hormonal ab-
normalities. Similarly, a third study using Cortavance for 14 days showed a sig-
nificant decrease in clinical signs, pruritus, and TEWL in absence of side effects,
suggesting a positive effect of hydrocortisone aceponate on skin barrier function.
Another RDBPCT showed promising effects of Cortavance as prophylactic treat-
ment (twice weekly), able to prolong the remission time in atopic dogs. Finally, more
recently, the immunologic effects of Cortavance have also been assessed in 2 other
studies performed in the United States and Japan. In the first study, the investi-
gators showed that once-daily Cortavance spray for 14 days is able to interfere with
intradermal testing (IDT) in dogs, and a minimum of 2 weeks is necessary to avoid
such effect on IDT. In addition, this was the first study showing that Cortavance
may be able to induce, histologically, a significant decrease in dermal thickness that
may be present. In addition, Cortavance may also induce, when used daily for 3 weeks,
a significant reduction (36.0% decrease) in the post-adrenocorticotropic hormone
cortisol level. However, Cortavance did not have any effect on peripheral
CCR4+CD4+ T-lymphocytes. Altogether, these studies showed a significant benefi-
cial clinical effect of Cortavance in the treatment of mild canine AD as preventive or as
management therapy. In addition, they show a large margin of safety of Cortavance in
both short-term and long-term treatment of canine AD.

An alternative to topical GCs is CIs (tacrolimus and cyclosporine). Only 3
RDBPCTs have been published on the use of tacrolimus for localized lesions of
AD in dogs, 2 of which investigated the use of the 0.1% and the 0.3% formul-
ation. In all 3 studies, the use of tacrolimus, although expensive, was very promising in
treating localized atopic lesions with minimal side effects. In all studies, most dogs
enrolled were able to achieve a treatment success (defined as >50% reduction in clin-
ical signs from baseline) after 4 or 12 weeks of treatment. Mild irritation was noticed in
a minority of cases after application and a lack of hematological and biochemical
changes was reported. Detectable levels of tacrolimus were present in the blood at
the end of the study; however, tacrolimus concentration was below toxicity limits.
When 0.3% tacrolimus ointment was used, a fourfold increase in tacrolimus concen-
trations was observed in the blood of dogs using 0.3% ointment. Due to equal efficacy
and lower blood levels of tacrolimus, the 0.1% ointment is recommended as a safer
choice. Cyclosporine, another calcineurin inhibitor, has been recently investigated
as a topical treatment option for canine AD. In a placebo-controlled clinical study,
the investigators showed a significant clinical efficacy (localized lesions of
moderate-severe AD) and moderate speed of action (21 days) of a nanotechnology
pharmaceutical formulation of cyclosporine able to penetrate the epidermis, guaran-
teeing good absorption and dermal action. On days 21 and 45 after treatment, a
significant reduction in clinical and pruritus score was seen in the treatment group
compared with placebo, showing a rapid and effective action of the
nano-compound in absence of side effects. However, more studies are needed to confirm the beneficial effect of this formulation in affected dogs.

Without a doubt, new-generation GCs and CIs are the most effective topical anti-inflammatory drugs used in canine AD. They are not only able to interfere with the inflammatory cascade, but also decrease pruritus. However, due to cost or potential side effects, their use may be limited. Good alternative medications that can be used as glucocorticoid-sparing drugs include topical antihistamines, local anesthetics, and skin barrier-repairing agents.

Antihistamines (H1 receptor antagonists) acts on histamine receptors, competitively blocking the formation of histamine-receptor complex. Thus, they inhibit the histaminic cascade after histamine is released, with some antihistamines able to inhibit mast cell degranulation as well. Common antihistamines used in veterinary dermatology include diphenhydramine, hydroxyzine, and cetirizine. Although inexpensive and extremely safe, their efficacy has been historically low in treating allergic conditions in dogs; however, the lack of efficacy of antihistamine in canine AD may be because histamine is not the major player in cutaneous inflammation in atopic dogs and also because antihistamines are not able to dislodge histamine from its receptors once they are bound. Unfortunately, the efficacy of topical H1 (diphenhydramine) and H4 (JNJ7777120 and JNJ28307474) antagonists has been shown to be low in recent studies. Topical diphenhydramine was able to reduce clinical signs of AD only approximately 20% to 38% after 28 and 56 days of use, respectively. Similarly, H4 antagonists, were not able to prevent skin lesions in a canine model of AD. These 2 studies indicate a potential use of topical antihistamines in canine AD, although more studies are needed to fully evaluate the usefulness of such medications in canine AD.

Local anesthetics have been used in clinical practice to alleviate the clinical signs of allergic dermatoses in dogs. In particular, the use of pramoxine as shampoo or cream rinse is of common use, although not many clinical trials have been published on its efficacy in dogs. Only 1 crossover open clinical trial has evaluated the efficacy of 2 topical formulations of pramoxine cream rinse (Relief, Bayer, Shawnee, KS, USA; Derma-Soote, Vetoquinol, Fort Worth, Tx, USA) in atopic dogs for a total of 4 weeks. At the end of the study, pramoxine was judged effective (51%–75% reduction in pruritus) by 41% of the owners. The post-treatment antipruritic effects lasted for 48 hours.

SKIN BARRIER–REPAIRING AGENTS

The use of anti-inflammatory/antipruritic topical mediations is essential in the treatment of allergic conditions in dogs. However, recent studies have shown that a skin barrier alteration, primary and/or secondary in nature, is present in both human and canine atopic skin. These results have led researchers and clinicians to look into therapies focused on ameliorating the skin barrier defect in allergic patients. In particular, topical fatty acids and (pro)ceramides have been largely used as adjuvant therapies for the treatment of canine AD. A few studies have been published on the effects of topical skin barrier–repairing agents showing a normalization of the epidermal lipid lamellae and skin lipids. However, the clinical effects of such products have been demonstrated in only a few clinical trials, showing an overall mild to moderate efficacy. The use of essential fatty acids (EFAs), as adjuvant therapy for allergic skin conditions and dry skin, has been adapted in the clinical practice for decades. Essential fatty acids, in form of ω-3 and/or ω-6, have been administered as oral supplementation or through commercially available EFA-enriched diets. Only recently, the use of
essential oil topical products has been considered as a potential alternative for delivering unsaturated EFA to affected skin. In 2011, an 8-week RDBPCT was performed in Germany comparing the clinical effects of a spot-on formulation containing essential oils and unsaturated fatty acids (Dermoscent Essential 6 spot-on, Adventix, Burlington, ON, Canada) with a spray containing similar, although different, oils and fatty acids (Dermoscent Atop 7 spray). The outcomes measured included a clinical assessment, pruritus score, and skin barrier assessment (TEWL) at the beginning and at the end of the study. At the end of the study, there was a significant reduction in clinical signs (40% and 79% for spot-on and spray, respectively), pruritus score (32% and 43%), and TEWL (spray formulation). Finally, no side effects were reported for any of the treatments. The same research group performed another RDBPCT analyzing the effects of the spot-on formulation against placebo over an 8-week period. The dogs were divided in mildly or moderately/severely affected atopic dogs. At the end of the study, a significant improvement of clinical signs and pruritus was seen in the treatment group. More recently, another RDBPCT analyzing the use of a topical lipid emulsion containing ceramides, fatty acids, and 18-β-glycyrrhetinic acid over a 3-month period was published. After the first month, a reduction of ≥50% in pruritus score was achieved in 50% of dogs; however, this beneficial effect was lost at the 3-month mark.

An alternative to essential oils and fatty acid topical formulations is the use of topical products containing a combination of ceramides, cholesterol, and fatty acids. In fact, early studies in people showed that products containing a specific molar ratio of ceramide, cholesterol, and fatty acids (3:1:1) to mimic the ratio naturally present in the skin were highly beneficial to improve skin lesions in atopic patients. In veterinary medicine, the first study, showing a beneficial effect of a spot-on product containing such molar ratio was published in 2008. In that study, the investigators used a spot-on formulation (Allerderm spot-on by Virbac) every 3 days for 6 consecutive times. After 6 treatments, a significant reorganization of the intracorneal lipids, due to a possible increase in production and secretion of endogenous stratum corneum lipids, was seen. Another proof-of-concept study was performed a few years later analyzing the expression of ceramides, cholesterol, and fatty acids in the stratum corneum of atopic dogs before and after 6 applications of Allerderm spot-on. At the end of the study, the investigators reported a significant increase in ceramide content and a more homogeneous distribution of protein-bound lipid content in the stratum corneum compared with before treatment. These studies were followed by 2 clinical trials evaluating the clinical benefits of Allerderm spot-on on atopic dogs; both studies gave similar results. The use of Allerderm spot-on, applied twice weekly for 4 to 12 weeks, was associated with a significant decrease in clinical signs compared with baseline scores; however, no benefits were seen for pruritus and barrier function (TEWL). These studies demonstrated that the application of such products might improve the lipid biosynthesis and distribution in the stratum corneum ameliorating the skin barrier, however, its usefulness in clinical practice still needs additional studies.

The results obtained by Allerderm spot-on were confirmed by a more recent study assessing the clinical and ultrastructural changes in atopic dogs before and after application of ceramide-based moisturizers for 28 days. The treatment involved the daily use of a moisturizing cream containing ceramide, cholesterol, and fatty acids (ration 3:1:1) (Atobarrier Cream, Aestura, Hangang-daero, Yongsan-gu, Seoul, Seoul, Korea) associated with a weekly moisturizing shampoo (Dermally shampoo, Dechra, Laewood, KS, USA). At the end of the study, a significant decrease in clinical signs, pruritus, and TEWL associated with an increase in skin hydration was reported. As
far as the ultrastructural study, it showed a significant increase in thickness and continuity of the lipid bilayer.

Other skin barrier–repairing products that have increased in popularity in the past few years are topicals containing plant-derived sphingosines (phytosphingosines). Sphingosines are natural derivates of ceramides that have been associated with significant anti-inflammatory, antimicrobial, and barrier-repairing activity. A recent study in France evaluated the barrier-repairing activity of a mousse containing phytosphingosines, raspberry oil, and lipids (Douxo Calm mousse, Ceva, Paris, France) in an experimental canine model. At the end of the study, there were no significant changes in TEWL or pH; however, a significant reduction of proliferation markers (ki-67) and B-lymphocytes and dendritic cells (BLA36) was seen in the treated compared with the untreated skin, suggesting a significant effect of phytosphingosines on inflammation and proliferation.

Altogether, these studies have shown that topical skin barrier–repairing agents have a significant benefit in treating canine AD. In particular, they are able to reduce cutaneous inflammation and restore intracorneal lipids normalizing the skin barrier of atopic dogs.

SYSTEMIC THERAPIES

Many systemic therapies have been investigated and routinely used in dogs affected by AD. As for the topical medications, it is important to recognize pros and cons of systemic therapies. The most important limitations of these drugs are cost, side effects, and lag phase. Because of their diversity in lag phases, some therapeutic options are more suitable for treating acute flares (eg, GC, oclacitinib), whereas others are more indicated for maintenance and/or prevention of flares (eg, allergen-specific immunotherapy, cyclosporine, antihistamines). This section is more focused on novel therapies (oclacitinib and lokivetmab) with a brief update on older therapies (cyclosporine).

Oclacitinib is a Janus kinase (JAK) inhibitor recently approved for treatment of allergic pruritus in dogs. There are 4 main types of JAK present in mammalian cells (JAK1, JAK2, JAK3, and TYK2). Of those, JAK1 is the JAK mainly involved in the inflammatory response, whereas JAK2 and 3 and TYK2 are mainly involved in cell differentiation, hematopoiesis, and homeostasis. Mechanistically, once a cytokine binds to the specific receptor, this dimerizes, allowing the autophosphorylation of JAK leading to the activation of the signal intermediate signal transducer and activator of transcription (STAT) proteins. Once activated, STAT proteins (7 STATs have been identified in mammalian cells) will migrate to the nucleus, leading to DNA transcription and regulation of gene expression. JAK/STAT signaling is critical for cytokine signaling and signal transduction of many proinflammatory, pro-allergic, and pruritogenic cytokines (eg, interleukin [IL]-2, IL-4, IL-6, IL-13, and IL-31). Oclacitinib had increased popularity almost immediately after its lunch on the US market due to its rapid action associated with few side effects. Oclacitinib is mainly a JAK1 and 2 inhibitor; however, a slight affinity for TYR2 and JAK3 has been reported as well. Its affinity profile explains the significant inhibition of inflammatory cytokines (IL-2, IL-4, IL-6, IL-13, and IL-31) and a minimal effect on hematopoietic cytokines (erythropoietin, granulocyte/macrophage colony-stimulating factor, IL-12, and IL-23). Pharmacologically, oclacitinib maleate is rapidly (plasmatic peak <1 hour) and almost completely (bioavailability of 89%) absorbed orally, independently from the prandial state, with a half-life of 4 to 6 hours, and a lack of cumulative effect over 168 days. Because of its speed of action, oclacitinib has been compared with prednisolone and dexamethasone in an experimental canine model of pruritus in which IL-31 was injected after the
administration of each drug. Prednisolone was able to inhibit the induced pruritus when administered 10 hours before the administration of IL-31, dexamethasone was able to reduce the pruritus up to 10 hours before IL-31 administration, whereas oclacitinib inhibited IL-31-induced pruritus when given 1, 6, 11, and 16 hours before IL-31 administration, making these compounds very similar from the clinical point of view. As far as efficacy, few studies have assessed the clinical benefits and side effects of oclacitinib in treating allergic skin diseases in dogs. The first 2 studies were very similar and showed that oclacitinib is a powerful drug, mainly active against pruritus. Oclacitinib was able to significantly reduce the pruritus within 7 days, with some improvement evident within 24 hours from administration. In the second study, oclacitinib was administered for 112 days. Over 28 days of treatment, a reduction in the pruritus score of 47.4% and 10.4% was detected in the oclacitinib and placebo groups, respectively; a reduction of 29.5% and 6.5% was seen within the first day of administration. From days 28 to 112, both the pruritus and clinical lesion scores remained unchanged. Minimal clinical and hematological abnormalities were reported in both studies. These studies were followed by a long-term compassionate use study combining the information from dogs previously exposed to oclacitinib for a mean time of 401 days. The side effects reported in this study were also very similar to previous findings, highlighting the possibility of urinary tract infections, vomiting, otitis, pyoderma, and diarrhea. Four percent of dogs (mean age: 9.8 years) were euthanized because of confirmed or suspected malignancy. In addition, 19% of dogs developed new dermal, epidermal, or subcutaneous masses of unknown origin. There were no hematological abnormalities reported in the study.

Based on these exciting preliminary data, oclacitinib has significantly increased in popularity among clinicians, posing the question of whether oclacitinib would be more beneficial in treating AD than older systemic therapies such as GCs and cyclosporine. Thus, a first study compared the use of oclacitinib with prednisolone over 28 days. Once again, pruritus and clinical signs were assessed, showing no difference between the 2 treatments after 4 hours, 6 days, and 18 days. On the opposite hand, as expected, oclacitinib performed much better than cyclosporine in another prospective RDBPCT over 84 days of treatment at label doses. In that study, a significantly higher reduction in pruritus score was seen in the oclacitinib group on days 1, 14, and 28, whereas a significant difference was seen only on day 14 for the clinical score. Because of the well-known long lag phase of cyclosporine, more recently, a study evaluated the combined use of oclacitinib and cyclosporine, assessing the clinical safety of such combination over a 21-day trial. At the end of the study, the investigators did not report any abnormalities except diarrhea in 2 dogs receiving both drugs.

Again, due to the numerous similarities between oclacitinib, GCs, and cyclosporine, potential complications (urinary tract infections), reported in long-term use of these latter 2 medications, were evaluated for oclacitinib in a very recent study. In that study, dogs receiving oclacitinib over 180 to 230 days did not show any signs (clinical or microbiological) of urinary tract infections. These studies indicate the usefulness of oclacitinib as good and safe alternative to other immunomodulatory drugs routinely used in veterinary dermatology to treat adult dogs affected by AD (eg, GC and cyclosporine).

Another treatment option that has acquired increasing popularity in treating canine AD is a caninized monoclonal anti-canine IL-31 antibody: lokivetmab. Lokivetmab was designed based on a recent study showing a role of IL-31 in canine pruritus using a canine experimental model. However, whether IL-31 plays a significant role in canine AD is still controversial. In fact, in the original study, only 57% of dogs with naturally occurring AD (detection limit 13 pg/mL) had a detectable serum level of IL-31. However, in a more recent study, using a canine model of AD, the investigators were able to...
detect IL-31 in all the samples analyzed (~40–50 pg/mL) and similar results were recently presented\textsuperscript{68} at the European Veterinary Dermatology Meeting showing the presence of IL-31 in the serum of 243 privately owned atopic dogs and 55 normal dogs using a more advanced ultrasensitive enzyme-linked immunosorbent assay technology able to detect extremely low amounts of protein in serum (femtomolar level of 531 fg/mL and 13,541 fg/mL in healthy and atopic dogs, respectively).

Lokivetmab is the first biologic commercially available for the treatment of allergic conditions in dogs. Its mechanism of action is quite simple: once injected, lokivetmab recognizes and binds to naturally produced IL-31, making it unavailable to bind to its receptor and trigger the pruritic cascade. Because foreign antibodies are readily recognized by the host’s immune system and destroyed, lokivetmab was made fully caninized (90% or more of the antibody structure is similar to antibody produced naturally in dogs) so as to avoid recognition and last longer. This type of technology has been largely used in human medicine to make humanized monoclonal antibodies to treat several immunologically driven diseases (eg, rheumatoid arthritis, psoriasis, AD). Since lokivetmab was initially commercialized, a few clinical studies\textsuperscript{69–71} have been published assessing its efficacy and safety in atopic dogs.

The first study involved atopic dogs throughout the United States.\textsuperscript{69} Dogs were assigned to receive a single subcutaneous injection of different dose of lokivetmab (0.125, 0.35, and 2 mg/kg) or placebo and monitored for clinical efficacy (pruritus and clinical signs) for 56 days. At full dose, a significant decrease in pruritus score was seen within 1 to 3 days, followed by a decrease in clinical signs after only 7 days. After 28 days, the success rate for the pruritus (decrease of \geq 50\% in score compared with baseline) was between 21\% and 57\%, depending on the dose used. Similarly, the success rate for the clinical score varied between 13\% and 46\% based on the dosage. Furthermore, pharmacokinetic data showed that, at full dose, the mean peak serum concentration of lokivetmab is 10 μg/mL observed after 9.8 days (2 mg/kg) with a mean half-life of 16 days.\textsuperscript{69} Similar results were evident from a clinical field trial\textsuperscript{70,71} evaluating the long-term efficacy and safety of lokivetmab for atopic dogs. In that study, lokivetmab was administered to atopic dogs for 9 consecutive months at monthly intervals. At the end of the trial, 76\% of dogs were assessed as being "normal," whereas 59\% were assessed as clinically “in remission.” Mild side effects were recorded and no immunogenicity (ie, anti-lokivetmab antibody development) was seen in any dog. Finally, a noninferiority study\textsuperscript{71} compared the efficacy of lokivetmab with cyclosporine. In that study, atopic dogs were enrolled and assigned to receive monthly lokivetmab or daily oral cyclosporine for 3 months. Lokivetmab was not inferior to cyclosporine for either pruritus or clinical signs, with an overall response to treatment of 68.5\% and 72.5\% by the owner and 74.0\% and 72.9\% by the investigator for cyclosporine and lokivetmab, respectively.

These studies altogether show that lokivetmab is a safe and effective treatment alternative to systemic GC and cyclosporine.

Cyclosporine has been considered a good GC-sparing agent for the past 20 years. Many of the clinical studies, proving the efficacy and safety of cyclosporine in dogs affected by AD, have been published in the past 2 decades. Cyclosporine is widely recognized to be highly effective in the treatment of canine AD and associated with minimal side effects. The author refers the reader to previously published reviews on cyclosporine efficacy in atopic dogs.\textsuperscript{72–77}

Recent studies have been mainly focused on the effects of cyclosporine on skin barrier function, skin microbiota, and effect on T-cell subtypes. In particular, one open study\textsuperscript{78} analyzed the effects of cyclosporine on TEWL, as indirect measurement of skin barrier integrity, in severely affected atopic dogs. The investigators were able...
to show that although a significant decrease in clinical signs was present after the second week on treatment, a significant decrease in TEWL, in selected areas, was detected from the first week on cyclosporine. Another single-blinded, randomized, placebo-controlled study\textsuperscript{75} evaluated the effect of cyclosporine on skin barrier integrity on a colony of atopic beagles before and after chronic stimulation with house dust mites. In that study, the investigators showed that 28 days of cyclosporine did not have any significant effect on skin immunologic milieu (IL-2, IL-4, IL-10, IL-13, interferon-\(\gamma\), tumor necrosis factor-\(\alpha\), and transforming growth factor-\(\beta\)) or skin barrier markers (canine antimicrobial peptides, filaggrin 2, and caspase 14) despite evident improvement of physical signs. Similarly, a lack of effect of cyclosporine on the skin microbiota was evident from another recent study\textsuperscript{80} using Maltese-beagle atopic dogs. In particular, the investigators showed that both cyclosporine and prednisone administered for 1 month were not associated with any significant changes in the cutaneous microbiota (bacteria, fungi, and viruses). Finally, very recently, the effect of cyclosporine on lymphocyte subpopulations also has been investigated to better understand the specific immunomodulatory effect of this compound on the immune system. In that controlled study,\textsuperscript{81} the investigators showed that 90 days of cyclosporine therapy, although significantly decreasing the clinical signs, did not modify the circulating T-cell ratio (CD4/CD8) and number of T-regulatory cells in atopic dogs. Thus, new studies have confirmed the beneficial clinical effect of cyclosporine for atopic dogs, but also showed that this compound has little effect on alteration of skin barrier, lymphocytic subpopulations, and cutaneous microbiota in atopic dogs.

**ALTERNATIVE THERAPIES**

The research of alternative therapies to treat canine AD has seen a tremendous increase in the past decade. In particular, researchers have invested in searching for more natural compounds with fewer side effects able to reduce or completely eliminate the needs of medications generally used for AD (eg, GC, cyclosporine, oclacitinib). The earliest and most repeated attempt was done looking into probiotics as a potential tool to reduce or prevent clinical signs of AD in dogs.\textsuperscript{82–86} In particular, the use of *Lactobacillus rhamnosus* has been shown to be effective in preventing the development of AD in a canine model when given in utero (from the third week of gestation until lactation) and continued in the offspring from the third week to 6 months of age.\textsuperscript{82} Immunologic and structural (skin barrier function) benefits were still evident after 3 years from the administration.\textsuperscript{83,84} More recently, a study,\textsuperscript{85} comparing cetirizine with *Lactobacillus paracasei K71*, showed a similar reduction in clinical signs (38.1% vs 45.8%) and pruritus (38.1% vs 26.8%) scores in mild cases of AD over 12 weeks of treatment. Similar results were confirmed by using *Lactobacillus sakei probio-65* after 8 weeks in dogs with severe AD.\textsuperscript{86} Altogether, these studies suggest that the administration of probiotics could be beneficial in preventing or reducing the clinical signs (and drugs) of AD in dogs. However, it is essential to keep in mind that not all bacteria act as probiotics, and particular attention needs to be applied to the choice of probiotics to be administered to optimize their beneficial effects.

Other treatments reported to be useful in reducing the clinical signs or the need of drugs to treat atopic dogs have been studied. In particular, oral vitamin E, associated with fexofenadine, has been shown to be highly effective in reducing clinical signs in moderate cases of AD after 8 weeks of treatment when compared with placebo plus fexofenadine (96% vs 89%, respectively).\textsuperscript{87} The investigators also reported an increase in circulating vitamin E and an increase in total antioxidant capacity. Similarly, the use of oral vitamin D has been shown to be promising when used in mild to
moderate cases of AD for 8 weeks. As in the vitamin E study, an increase in circulating vitamin D was detected. In both studies, a lack of side effects was reported.

Other alternative therapies shown to be effective in the treatment of canine AD include the use of procaine (neural therapy), ultrapure water, pentoxifylline plus polyunsaturated fatty acids (PUFAs), and endocannabinoids, whereas other options have not been associated with a significant or questionable improvement of canine AD (eg, cold laser therapy, homeopathy, fluoxetine, CCR4 inhibitors, aminopterin) or associated with moderate to severe side effects (eg, masitinib).

Briefly, the use of procaine intravenously and intradermally (in affected areas), showed a significant reduction of 82.6% and 77.4% in clinical signs and pruritus score with 88% of dogs reaching a reduction of both scores of ≥50% after 13 weeks of treatment in absence of side effects. Furthermore, a maintained improvement of the clinical signs was seen in 55% of the dogs enrolled after 19 weeks from last injection.

Recently, a placebo-controlled clinical trial evaluated the efficacy of weekly Allermyl shampoo (ceramides and EFAs) using ultrapure soft water compared with Allermyl shampoo using tap water in moderate cases of canine AD over a 4-week period. Ultrapure soft water is characterized by low hardness, low calcium and magnesium, and high sodium compared with tap water. The study showed a significant decrease in clinical signs (21% vs −0.45%), pruritus (24.0% vs 3.6%), and TEWL (46.4% vs −6.0%) for the treatment group compared with the control.

Pentoxifylline is a nonselective phosphodiesterase enzyme inhibitor able to decrease fibronectin, production of proinflammatory cytokines, and leukocyte response to interleukins, and impairs T-lymphocyte binding to keratinocytes, decreases fibroblastic activity, and with long-term use, may decrease fibrosis. Although clinically used, only 1 placebo-controlled, randomized study has been published assessing its efficacy in treating canine AD. Pentoxifylline was administered orally at the dosage of 20 mg/kg every 8 hours, alone (group I) or in combination with oral PUFAs (group II), for 60 days. On days 30 and 60, a significant reduction in both clinical signs and pruritus scores was seen in both treatment groups compared with placebo (group III) and with baseline. However, the combination of pentoxifylline and PUFAs was more efficacious than pentoxifylline alone.

Last, the oral use of naturally occurring bioactive lipid endocannabinoid-like compounds has been investigated in dogs affected by AD. In particular, an open-label clinical trial using ultra-micronized palmitoylethanolamide at 10.9 mg/kg per day for 8 weeks showed a significant reduction in both clinical signs (day 28: 31.6%; day 56: 48.2%) and pruritus (day 28: 26%; day 56: 36.8%), and an increase in quality of life. This study, although it is the first one published in dogs, is very promising.

As far as homeopathic remedies for treating AD in dogs, only 1 small pilot study showed a potential benefit of individualized remedies in canine AD. However, due to the very low number of dogs enrolled and the lack of a controlled, blinded, randomized clinical trial, the use of homeopathy is not justified at the moment. The use of cold laser therapy was investigated in a placebo-controlled, clinical trial. However, after 5 weeks of treatment, no difference in clinical signs and pruritus was present between low-level laser therapy (cold laser) and placebo. Finally, a double-blinded, placebo-controlled crossover 2-month clinical trial evaluated the efficacy of fluoxetine for severe AD, showing no efficacy after 2 months of fluoxetine.

FUTURE THERAPIES

Looking at the future, it is possible that safer and more targeted compounds will be available for canine AD. Specifically, biologics targeting molecules involved in the
treatment of specific clinical subtypes of AD are desirable. On the other hand, the use of viral-particle-associated cytokines or bacterins have also been studied as potential treatments for allergies in animals. Their efficacy is variable but promising in the face of mild side effects. Among others, humanized anti-interleukin antibodies (targeting IL-4, IL-13, IL-17, and IL-22) have been studied, or are currently under evaluation, for the treatment of human AD. Along with anti-interleukin antibodies, the use of anti-human IgE and anti-IL-31 receptor antibodies have been highly promising as well. In veterinary medicine, the only biologic approved is lokivetmab. It is plausible to assume that more biologics will be readily available in the near future; however, based on the complexity of the atopic disease, instead of a single monoclonal antibody, maybe the use of cocktails of monoclonal antibodies may increase the efficacy of this therapeutic option.

SUMMARY

In conclusion, canine AD is an extremely complex clinical syndrome characterized by different clinical manifestations and therapeutic response. Because of its complexity, multiple therapies have been evaluated in different clinical subtypes, with sometimes contrasting results. At the moment, a pool of few compounds represent the “core” of treatment options for canine AD (eg, GC, cyclosporine, oclacitinib). However, alternative drugs and topical therapies have been looked at with increased interest due to their low toxicity and high efficacy, specifically if associated with “core” medications. Furthermore, it is fundamental to remember to strive for preventive medicine using compounds able to delay rather that treat flares and skin infections in atopic dogs. In addition, it is important to recognize the difference in drugs more suited for treating flares and drugs more effective in preventing the flares. Treatment options should be regularly reassessed and adjusted based on the specific needs of patients and their owners. The key of a successful treatment for canine AD often combines high efficacy with low cost and mild side effects.

REFERENCES


43. Marsella R, Conregianni L, Ozmen I, et al. Randomized, double-blinded, placebo-controlled pilot study on the effects of topical black currant emulsion enriched in essential fatty acids, ceramides and 18-beta glycyrrhetinic acid on clinical signs


60. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with


68. Messamore JE. An ultrasensitive single molecule array (Simoa) for the detection of IL-31 in canine serum shows differential levels in dogs affected with atopic dermatitis compared to healthy animals. Vet Dermatol 2017;28:546.


